While Regulus Therapeutics Inc has overperformed by 7.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RGLS fell by -31.29%, with highs and lows ranging from $2.90 to $0.83, whereas the simple moving average jumped by 25.38% in the last 200 days.
On March 27, 2025, Wells Fargo Upgraded Regulus Therapeutics Inc (NASDAQ: RGLS) to Overweight. A report published by Oppenheimer on August 02, 2024, Initiated its previous ‘Outperform’ rating for RGLS. Leerink Partners also rated RGLS shares as ‘Outperform’, setting a target price of $6 on the company’s shares in an initiating report dated March 18, 2024. B. Riley FBR Inc. Initiated an Neutral rating on March 28, 2018, and assigned a price target of $1. Leerink Partners initiated its ‘Outperform’ rating for RGLS, as published in its report on January 05, 2018. Chardan Capital Markets’s report from June 13, 2017 suggests a price prediction of $2.50 for RGLS shares, giving the stock a ‘Buy’ rating. Wedbush also rated the stock as ‘Outperform’.
Analysis of Regulus Therapeutics Inc (RGLS)
To gain a thorough understanding of Regulus Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -95.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 10.52, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and RGLS is recording an average volume of 1.15M. On a monthly basis, the volatility of the stock is set at 13.15%, whereas on a weekly basis, it is put at 10.81%, with a gain of 19.37% over the past seven days. Furthermore, long-term investors anticipate a median target price of $10.83, showing growth from the present price of $1.91, which can serve as yet another indication of whether RGLS is worth investing in or should be passed over.
How Do You Analyze Regulus Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 19.71%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 67.87% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RGLS shares are owned by institutional investors to the tune of 67.87% at present.
